European Day

Antibiotics: first case of penicillin-resistant group B streptococcus reported in Italia

Focus on responsible use: in 2025, the rates of resistance to the main classes of antibiotics for the eight pathogens under surveillance remain high and, in some cases, are on the rise

 Adobe Stock

4' min read

Translated by AI
Versione italiana

4' min read

Translated by AI
Versione italiana

A strain of Streptococcus agalactiae (Group B Streptococcus, or GBS) resistant to penicillin – the first-line antibiotic used both for the treatment of invasive infections and for intrapartum antibiotic prophylaxis – has been identified in Italia for the first time this year. This has been reported by the Italian National Institute of Health ahead of European Antibiotic Awareness Day on 18 November. The occasion also serves as a reminder that ‘rates of antibiotic resistance in Italia generally remain high, although there are signs of improvement’.

The case

In 2024, the WHO had, for the first time, classified penicillin-resistant Group B Streptococcus as a medium-priority pathogen, highlighting how the loss of efficacy of beta-lactam antibiotics against this microorganism represents an emerging threat to global public health, with a particular impact on the most vulnerable groups and on neonatal health.

Loading...

The bacterium was isolated in February 2026 from a blood culture taken from an adult patient by the Piacenza Local Health Authority (AUSL), which sent the isolate to the Italian National Institute of Health (ISS) for confirmation of resistance and molecular characterisation. Laboratory analyses and genomic sequencing confirmed that the strain (serotype Ia, Sequence Type 23) had an MIC value of 0.25 mg/L, linked to previously known and ‘de novo’ identified point mutations in the penicillin-binding protein genes pbp2a and pbp2x, and was found to be resistant to other antibiotics, such as levofloxacin, erythromycin and tetracycline.

This first national isolation case, published in *Eurosurveillance*, “means we must remain vigilant across the country to safeguard the effectiveness of prevention and treatment protocols”, the Institute explains.

Data for Italy

Antibiotic resistance rates in Italy generally remain high, although there are signs of improvement. The use of hydroalcoholic hand sanitiser in hospitals has also risen slightly, whilst still falling far short of the rates recommended by the WHO. ‘Combating antibiotic resistance to preserve the effectiveness of antibiotics in treating infections and their consequences for health and healthcare systems. This is the key message of the event that we wish to share with all stakeholders,’ says Anna Teresa Palamara, head of the Department of Infectious Diseases at the ISS. - Combating resistance requires a range of integrated measures, including surveillance, research, health policies, and the development of new diagnostic, preventive and therapeutic strategies. This is a complex problem that calls for long-term collaborative efforts, which our system is called upon to address.”

European Day

The ECDC points out that, every year, more than 35,000 people in the European Union die from infections caused by antimicrobial-resistant microorganisms – a death toll comparable to that of influenza, tuberculosis and HIV/AIDS combined. Furthermore, 4.3 million patients contract at least one healthcare-associated infection during their stay in hospital. One in three microorganisms detected in healthcare-associated infections consists of bacteria resistant to key antibiotics. This year’s theme is ‘Look after your children – use antibiotics only when prescribed by a doctor’ and focuses on children, a population group increasingly exposed to antibiotics even for common infections that do not require their use. This European initiative forms part of World AMR Awareness Week (WAAW), the global campaign on the prudent use of antimicrobials organised by the WHO, which takes place from 18 to 24 November.

Surveillance

• According to the AR-ISS surveillance programme in Italia, in 2025, the rates of resistance to the main classes of antibiotics for the eight pathogens under surveillance remain high and, in some cases, are on the rise; however, for other pathogen/antibiotic combinations, a downward or stable trend continues to be observed compared with previous years. For vancomycin-resistant Enterococcus faecium, the trend continues to show a worrying increase. (Please refer to the attached factsheet for detailed data; the full report will be published in the coming days)

• In Intensive Care Units, compared with other wards, higher rates of resistance were observed between 2015 and 2025 in K. pneumoniae, P. aeruginosa and carbapenem-resistant Acinetobacter spp. (37.8%, 20.0% and 87.3% respectively).

• With regard to data from the national surveillance programme for carbapenem-resistant Enterobacteriaceae (CRE) bacteraemia – one of the most serious infectious threats, according to the WHO – , in 2025 the incidence of reported cases shows a slight increase compared with 2024 and remains high compared with the period 2016–2021.

• 4,004 cases diagnosed and reported in 2025 confirm the widespread prevalence in Italia of carbapenem-resistant Enterobacteriaceae bacteraemia, particularly amongst hospitalised patients.

Loading...

• Central Italia is the region with the highest incidence of reported cases, followed by the South and the Islands.

• Those most affected are men aged between 60 and 79 who have been hospitalised and admitted to intensive care units.

The consumption of hydroalcoholic solution

According to the latest available data (725 healthcare facilities; all Italian regions and autonomous provinces represented), in 2025 the national median consumption of hydroalcoholic solution stood at 10.7 L/1,000 GDO (litres per thousand hospital bed-days) for routine hospitalisation, a slight increase compared with the 9.9 recorded in 2024 but still well below the WHO benchmark of 20 L/1,000 GDO. Consumption varies by clinical area: it is highest in intensive care (41.1 L/1,000 GDO) and lowest in orthopaedics (8.4 L/1,000 GDO). In the years following the COVID-19 pandemic, a gradual decline in consumption was observed across all areas; however, in 2025 there was a slight increase, and the number of facilities participating in the surveillance programme grew.

Copyright reserved ©
Loading...

Brand connect

Loading...

Newsletter

Notizie e approfondimenti sugli avvenimenti politici, economici e finanziari.

Iscriviti